Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
VERA Vera Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: VERA
Price (delayed)
$22.03
Market cap
$1.4B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3
Enterprise value
$1.4B
Highlights
VERA's equity has soared by 51% year-on-year but it is down by 7% since the previous quarter
The quick ratio has grown by 7% from the previous quarter but it has contracted by 3% YoY
The net income has plunged by 86% YoY and by 15% from the previous quarter
VERA's EPS is down by 46% year-on-year and by 9% since the previous quarter
Key stats
What are the main financial stats of VERA
Market
Valuations
Earnings
Shares outstanding
63.77M
Market cap
$1.4B
Enterprise value
$1.4B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.63
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$193.25M
Net income
-$175.46M
EBIT
-$167.95M
EBITDA
-$164.28M
Free cash flow
-$156.41M
Per share
Balance sheet
Liquidity
EPS
-$3
EPS diluted
-$3
Free cash flow per share
-$2.46
Book value per share
$8.39
Revenue per share
$0
TBVPS
$9.58
Total assets
$610.17M
Total liabilities
$75.17M
Debt
$54.47M
Equity
$535M
Working capital
$584.18M
Debt to equity
0.1
Current ratio
27.68
Quick ratio
26.94
Net debt/EBITDA
0
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-34.5%
Return on equity
-40.6%
Return on invested capital
-34.3%
Return on capital employed
-28.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VERA stock price
How has the Vera Therapeutics stock price performed over time
Intraday
-2.61%
1 week
-7.24%
1 month
16.81%
1 year
-50.98%
YTD
-47.91%
QTD
-8.28%
Financial performance
How have Vera Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$193.25M
Net income
-$175.46M
Gross margin
N/A
Net margin
N/A
VERA's operating income has dropped by 90% year-on-year and by 16% since the previous quarter
The net income has plunged by 86% YoY and by 15% from the previous quarter
Price vs fundamentals
How does VERA's price correlate with its fundamentals
Growth
What is Vera Therapeutics's growth rate over time
Valuation
What is Vera Therapeutics stock price valuation
P/E
N/A
P/B
2.63
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
VERA's EPS is down by 46% year-on-year and by 9% since the previous quarter
VERA's P/B is 52% less than its last 4 quarters average of 5.5 and 49% less than its 5-year quarterly average of 5.2
VERA's equity has soared by 51% year-on-year but it is down by 7% since the previous quarter
Efficiency
How efficient is Vera Therapeutics business performance
VERA's return on equity is up by 23% year-on-year but it is down by 3.3% since the previous quarter
The ROIC has grown by 17% YoY but it has contracted by 4.3% from the previous quarter
The ROA has increased by 12% year-on-year but it has declined by 4.2% since the previous quarter
Dividends
What is VERA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VERA.
Financial health
How did Vera Therapeutics financials performed over time
VERA's total assets is up by 46% year-on-year but it is down by 7% since the previous quarter
The total liabilities has increased by 14% year-on-year but it has declined by 4.3% since the previous quarter
VERA's debt is 90% smaller than its equity
VERA's equity has soared by 51% year-on-year but it is down by 7% since the previous quarter
Vera Therapeutics's debt to equity has decreased by 33% YoY but it has increased by 11% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.